Back to Search
Start Over
TCR engineered T cells for solid tumor immunotherapy.
- Source :
-
Experimental Hematology & Oncology . 6/20/2022, Vol. 11 Issue 1, p1-11. 11p. - Publication Year :
- 2022
-
Abstract
- T cell immunotherapy remains an attractive approach for cancer immunotherapy. T cell immunotherapy mainly employs chimeric antigen receptor (CAR)- and T cell receptor (TCR)-engineered T cells. CAR-T cell therapy has been an essential breakthrough in treating hematological malignancies. TCR-T cells can recognize antigens expressed both on cell surfaces and in intracellular compartments. Although TCR-T cells have not been approved for clinical application, a number of clinical trials have been performed, particularly for solid tumors. In this article, we summarized current TCR-T cell advances and their potential advantages for solid tumor immunotherapy. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 21623619
- Volume :
- 11
- Issue :
- 1
- Database :
- Academic Search Index
- Journal :
- Experimental Hematology & Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 157543361
- Full Text :
- https://doi.org/10.1186/s40164-022-00291-0